Biotech Updates: Acrivon CLIA Lab, Lilly M&A Spree, Defence Radiopharma COO
Acrivon launched a CLIA-certified lab. Eli Lilly disclosed over 5 trillion won in M&A and licensing. Defence Therapeutics named a new radiopharmaceutical COO.
IQVIA
CompanyAlso known as: IQVIA
Company Profile
IQVIA is an American multinational company that combines health information technology and clinical research services. It was formed in 2016 through the merger of Quintiles and IMS Health and is headquartered in Durham, North Carolina.
- Website
- https://www.iqvia.com
- Headquarters
- Durham, North Carolina, USA
- Founded
- 2016
- Stock Ticker
- NYSE:IQV
Related News
Lawmakers Probe Drugmakers Over China Clinical Trials as U.S. Seeks to Counter Biotech Rise
Lawmakers opened national security probes into Merck, AbbVie and others over China drug trials. A survey finds China closing in on U.S. biotech leadership, and HHS launched clinical trial reforms to counter the rise.
Proposed 2027 Insurance Rule Omits Copay Assistance Protections, Advocates Warn
The Trump administration’s proposed 2027 insurance regulation omits copay accumulator protections, allowing insurers and PBMs to continue diverting billions in manufacturer copay assistance from patients. Advocates warn that without action, rising out-of-pocket costs will further strain patients. The rule also fails to close a loophole for large group plans regarding essential health benefits.
AI Transforms Clinical Trial Design and Decentralized Trials, But Recruitment Challenges Persist
AI is transforming decentralized clinical trials, with over $650 million in recent funding and threefold faster patient recruitment. Experts warn that AI-optimized protocols may still struggle to recruit patients, emphasizing lean trial design and adaptive planning.
Global Drugmakers Expand Rare Disease Research Investment in Brazil Amid Persistent Funding Gaps
Global drugmakers are expanding rare disease research investment in Brazil, attracted by new regulations, genetic diversity, and the public healthcare system's data capabilities. Major companies including AstraZeneca, Biogen, and Roche have committed significant clinical research budgets to the country. Despite this progress, advocates warn that a significant global funding gap persists, with 95% of rare diseases still lacking an FDA-approved treatment.
BMS CELMoD Mezigdomide Doubles PFS in Myeloma as FDA Reviews Iberdomide
BMS's mezigdomide doubled progression-free survival in relapsed/refractory multiple myeloma at ASCO, while the FDA reviews iberdomide with a decision due by August 17. C4 Therapeutics has dosed the first patient in its Phase 2 MOMENTUM trial of cemsidomide.
AI's Mixed Impact on Pharma: Accelerating Drug Development While Facing Clinical Trial Realities
AI could compress drug development from 10-15 years to as little as six years, accelerating discovery and reducing late-stage trial failures. However, clinical trial execution remains heavily dependent on human oversight, with AI estimated to cut costs only 10-15% while facing regulatory and liability constraints. Major pharma companies like Gilead are investing in AI research centers despite practical limitations in trial implementation.
Global Generic Drugs Market Reaches $389 Billion, Poised for Growth to $675 Billion by 2033
The global generic drugs market reached $389 billion in 2024 and is projected to grow to $675 billion by 2033. In the U.S., generics account for 91% of prescriptions but only 18% of drug spending, saving over $373 billion annually. Biosimilar adoption remains below 20% despite some products reaching over 60% market share within three years.
Pharmaceutical Industry Shifts to Fewer, Larger AI-Driven Drug Development Partnerships
Global pharmaceutical R&D deal values surged 49% to $86.7 billion in 2025 as companies concentrate investments in AI-powered drug discovery platforms, with average deal sizes reaching a record $1.16 billion despite fewer total partnerships.
Medicus Pharma Reports Phase 2 Results for SkinJect, FDA Clears Teverelix Trial
Medicus Pharma reported Phase 2 SKNJCT-003 topline data showing 73% clinical clearance and 40% histological clearance at Day 57 in the 200μg cohort. Separately, the FDA cleared the company to begin a Phase 2b dose optimization study for Teverelix in advanced prostate cancer.